Achieve Life Sciences, Inc.
ACHVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAchieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. At a $669.1M market cap, Achieve Life Sciences, Inc. ranks as a small-cap company within healthcare. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Market Cap
$669.1M
Beta
2.31
P/E (TTM)
—
P/E (Fwd)
-9.95
EPS (TTM)
$-1.69
EPS (Fwd)
$-0.65
ROE
-845.0%
ROA
-29.2%
Cash
$187.3M
Total Debt
$14.9M
Free CF
$156.3M
52W Change
29.8%
Annual Financials
Cash vs Debt
Where ACHV stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, ACHV finished 8.69% above its 150-day moving average ($5.87) and 14.54% above its 200-day moving average ($5.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACHV overbought or oversold?
At the October 19, 2026 close, ACHV's RSI(14) was 27.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Achieve Life Sciences, Inc. holds $187.3M in cash against $14.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $156.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -845.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, ACHV tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ACHV has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Achieve Life Sciences, Inc.'s trajectory.